Health
Freiburg immunologists decipher anti-cancer drug’s mode of operation – News-Medical.net
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University…
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works. A team headed by Professor Dr. Michael Reth used cell cultures, healthy cells, and cells from cancer patients to investigate how CD20 organizes the nanostructures on the B cell membrane. If the protein is missing or Rituximab binds to it, the organization of the B cell surface…
-
Business21 hours agoThese 4 ASX mining stocks are rocketing as the rare earths boom intensifies
-
General18 hours agoBunbury man Stanley J Clemons sentenced for shooting neighbour’s dog
-
Noosa News21 hours agoLung cancer researchers identify ‘breakthrough’ patterns predictive of treatment success
-
Noosa News9 hours agoWarm weather could make way for rain with ‘damaging winds, large hail’